Ionis Pharmaceuticals IONS Payments For Transaction Costs Related To Sale Of Future Royalties
Payments For Transaction Costs Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:PaymentsForTransactionCostsRelatedToSaleOfFutureRoyalties.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported payments for transaction costs related to sale of future royalties of $0 in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's payments for transaction costs related to sale of future royalties has grown at a -100.0% compound annual growth rate (CAGR), from $10.43M to $0.
- What does payments for transaction costs related to sale of future royalties mean?
- Fees paid to execute a sale of future royalty rights.
- How do you interpret payments for transaction costs related to sale of future royalties?
- Higher costs relative to proceeds may indicate complex deal structures or high advisory fees.
- How does payments for transaction costs related to sale of future royalties compare across companies?
- Standard transaction cost reporting for corporate finance activities.